Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06038630 · ClinicalTrials.gov registry record · Phase 2
129Xe MRI Cardiopulmonary
A Phase 2 study of Anemia and Interstitial Lung Disease, sponsored by Bastiaan Driehuys.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT06038630: Recruiting Phase 2 study of Anemia and Interstitial Lung Disease, sponsored by Bastiaan Driehuys.
NCT06038630 is a Phase 2 study of Anemia and Interstitial Lung Disease that is actively recruiting participants, run by Bastiaan Driehuys. The registered enrollment target is 125 participants, below the 426-participant average among 72 other Anemia trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06038630, a Phase 2 study of Anemia and Interstitial Lung Disease, is actively recruiting participants, sponsored by Bastiaan Driehuys.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.
Primary Outcome
The investigators will validate the Hb (hemoglobin) correction model in anemia patients pre/post transfusion and blood donors pre/post apheresis.
Conditions Studied
Interventions
- DRUG Hyperpolarized Xe129
- OTHER Oxygen Administration
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2024-01-12 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
What NCT06038630 shows while recruiting
NCT06038630 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 426-participant average among 72 other Anemia trials with a reported enrollment target (71% lower).
The record links to 6 conditions, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which Hyperpolarized Xe129 is the first listed.
NCT06038630 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06038630 about?
NCT06038630 is a clinical study titled "129Xe MRI Cardiopulmonary". The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.
What is the current status of trial NCT06038630?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2024-01-12. Estimated completion is 2028-06-30.
What conditions does trial NCT06038630 study?
This clinical trial studies the following conditions: Anemia, Interstitial Lung Disease, Dyspnea, Chronic Thromboembolic Pulmonary Hypertension, Acute Pulmonary Embolism.
What interventions are being tested in trial NCT06038630?
The interventions under investigation include: Hyperpolarized Xe129 (DRUG), Oxygen Administration (OTHER).
Who is sponsoring clinical trial NCT06038630?
This trial is sponsored by Bastiaan Driehuys, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06038630 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06038630's enrollment target sits among peer trials
125 42nd of 72 higher than 31 of 72 other Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
Study of DISC-0974-201 in Participants With IBD and Anemia
RECRUITING · Phase 2
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Choline and Iron Deficiency
RECRUITING · Phase 2
-
Luspatercept for Clonal Cytopenias of Uncertain Significance
RECRUITING · Phase 2
-
Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI